Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized <i>WT1</i> Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet StudyDaniela Cilloni, David Grimwade, Tamara Weiss et al.|Journal of Clinical Oncology|2009Cited by 434
Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World StudyFrancesca Palandri, Massimo Breccia, Alessandra Iurlo et al.|Cancer|2024Cited by 10
Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinibFrancesca Palandri, Andrew Kuykendall, Monica Crugnola et al.|Cancer|2025Cited by 5
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter studyFrancesca Palandri, Elisabetta Abruzzese, Fabrizio Cavalca et al.|Leukemia Research|2025Cited by 4